Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

194
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
194
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

151
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
151
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

235
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
235
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

460
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
460

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Evaluation of Pectus Excavatum in Active Duty Military Patients.

Military medicine·2026
Same author

Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Evolution of AR and Non-AR Alterations in ctDNA of Patients with Metastatic Prostate Cancer Treated in the Phase III Alliance A031201 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Predictors of Respiratory Oscillometry Measurements in a Healthy Population.

Respiratory care·2025
Same author

Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer.

Clinical and translational science·2025

Related Experiment Video

Updated: Jan 7, 2026

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.6K

Concepts in Phase 1 Radiopharmaceutical Therapy Trial Designs: Lessons from the SNMMI Dose Optimization in

Michael J Morris1, Thomas A Hope2, Oliver Sartor3

  • 1Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|December 30, 2025
PubMed
Summary
This summary is machine-generated.

Radiopharmaceutical therapy offers a promising new approach for advanced cancer. Dose optimization is crucial for developing these novel cancer treatments, especially for refractory solid tumors.

Keywords:
FDASNMMIdosimetryphase 1radiopharmaceuticals

More Related Videos

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.1K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K

Related Experiment Videos

Last Updated: Jan 7, 2026

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.6K
Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.1K
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K

Area of Science:

  • Nuclear medicine
  • Oncology
  • Radiopharmaceutical therapy

Background:

  • Cancer remains a leading cause of death in the US, necessitating novel therapeutic strategies.
  • Advanced and refractory cancer patients have limited treatment options.
  • Radiopharmaceuticals are emerging as a significant area in cancer treatment development.

Purpose of the Study:

  • To summarize key insights from the Dose Optimization of Radiopharmaceutical Therapy Developmental Workshop.
  • To highlight stakeholder perspectives on radiopharmaceutical therapy development.
  • To emphasize the importance of dose optimization in advancing radiopharmaceutical treatments.

Main Methods:

  • A summary of discussions from a workshop convened by the Society of Nuclear Medicine and Molecular Imaging and the Food and Drug Administration.
  • Inclusion of perspectives from academia, industry, and regulatory bodies.
  • Focus on dose and schedule optimization for radiopharmaceutical therapies.

Main Results:

  • For patients with advanced, refractory solid tumors, the benefits of radiopharmaceutical therapy outweigh concerns about long-term toxicity.
  • The urgency of treating life-threatening cancer in these patients makes long-term risks less critical.
  • Phase 1 studies are vital for establishing optimal dosing and scheduling for subsequent trials.

Conclusions:

  • Radiopharmaceutical therapies hold significant promise for treating advanced and refractory cancers.
  • Dose optimization, particularly in early-phase trials, is essential for regulatory approval and clinical success.
  • The focus should be on maximizing therapeutic benefit for patients with limited survival.